USP to revise Part D drug guidelines
Executive Summary
U.S. Pharmacopeia's Model Guidelines Expert Committee will meet Nov. 1-2 to discuss revisions to the list of drug categories and classes to be used by Medicare Part D drug plans in developing formularies. The group will update the guidelines to account "for new Part D drugs and new therapeutic uses of Part D drugs." USP will submit draft revised guidelines and a final report to the Centers for Medicare & Medicaid Services by Jan. 30. The initial guidelines, issued in December 2004, were followed by about half of the prescription drug plans that submitted formularies to CMS (1"The Pink Sheet" Sept. 26, 2005, p. 17)...
You may also be interested in...
USP Formulary Guidelines Adopted By Half Of Medicare Drug Plans
About half of Medicare prescription drug plans submitted to CMS followed the formulary guidelines created by the U.S. Pharmacopeia
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.